Drugs / hMPV mRNA LNP 1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06237296 | Jan 2024 → Feb 2025 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hMPV mRNA LNP 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06237296 ↗ |
| Modality | Messenger RNA (mRNA) | “investigational mRNA Vaccine” NCT06237296 ↗ |
| Route | Intramuscular | “Route of administration:Intramuscular Injection” NCT06237296 ↗ |